Latest Herantis Pharma News & Updates
See the latest news and media coverage for Herantis Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage neurodegenerative disease drug developer
herantis.com- Headquarters
- Espoo, Finland
- Founded year
- 2008
- Company type
- Public company
- Number of employees
- 25–50
Last updated
Latest news about Herantis Pharma
In short: Herantis Pharma advanced its Parkinson’s therapy HER-096 toward Phase 2 trials following successful Phase 1b results and new strategic funding.
Company announcements
-
Herantis Pharma CEO presents at Copenhagen conference
He shares HER-096 updates, Phase 1 results, and EUR 8.0 million grant for Phase 2 study.
-
Herantis Pharma releases 2025 Annual Report
Report summarizes clinical progress, including completed Phase 1 for HER-096 with encouraging data, advancing to Phase 2 in Parkinson’s.
-
Herantis Pharma CEO and CSO discuss Parkinson's trial and funding
They cover HER-096 design, Phase 1b results, share issue, grant, and upcoming catalysts.
-
Herantis Pharma announces CSO presentation on HER-096 trial
Henri Huttunen presents Phase 1b safety, PK, and biomarker data at AD/PD 2026, supporting Phase 2 preparations for Parkinson's therapy.
Media coverage
-
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer's & Parkinson's Diseases
Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson's disease, announces that its Chief Scientific Officer, Henri Huttunen...
-
Herantis Pharma PLC (OHEL:HRTIS) Full Year 2025 Earnings Call Highlights: Promising Clinical ...
Herantis Pharma PLC (OHEL:HRTIS) showcases successful Phase 1B trial results and strategic funding efforts, while navigating financial hurdles for upcoming Phase 2 trials.
-
Herantis Pharma's losses deepened – Financing options under consideration | Kauppalehti
The drug developer does not yet have revenue, and the money goes to research on a promising drug candidate. Planning of the next research phase is already underway.
-
Herantis Pharma PLC HRTIS
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive...
Track Herantis Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Herantis Pharma competitors & trending companies
Browse news for competitors to Herantis Pharma and other trending companies.
Clene
BioArctic
Raya
Prilenia Therapeutics
Origami Therapeutics
Nura Bio
Tiziana Life Sciences
Revalesio
Spinogenix
QurAlis
Acelot
AlzeCure Pharma
Alzinova
VectorY Therapeutics
Mitochon Pharmaceuticals
NRG Therapeutics
Celosia Therapeutics
NeuroSense Therapeutics
Harness Therapeutics
Aquilus Pharmaceuticals
Dunad Therapeutics
Transposon Therapeutics
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies